Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF

Catalog # Availability Size / Price Qty
1906-SF-050
Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF Bioactivity
2 Images
Product Details
FAQs
Reviews

Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF Summary

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED50 for this effect is 1-6 μg/mL.
Source
Human embryonic kidney cell, HEK293-derived human CRACC/SLAMF7 protein
Human SLAMF7
(Ser23-Met226)
Accession # Q9NQ25
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminusC-terminus
Accession #
N-terminal Sequence
Analysis
Ser23
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
49 kDa
SDS-PAGE
65-75 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1906-SF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Data Images

Bioactivity Bioactivity View Larger

Recombinant Human CRACC/SLAMF7 Fc Chimera (Catalog # 1906-SF) inhibits anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells. The ED50 for this effect is 2-10 μg/mL.

SDS-PAGE SDS-PAGE View Larger

2 μg/lane of Recombinant Human CRACC/SLAMF7 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 65-75 kDa and 130-150 kDa, respectively.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: CRACC/SLAMF7

CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CRACC consists of a 204 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a 21 aa transmembrane segment, and an 88 aa cytoplasmic domain with one immunoreceptor tyrosine-based switch motif (ITSM) (2, 3). Within the ECD, human CRACC shares 54% and 52% aa sequence identity with mouse and rat CRACC, respectively. There are seven known isoforms of CRACC which are distinguished by deletions and/or substitutions in both their ECD and cytoplasmic domains. CRACC is expressed on the surface of NK cells, CD8+ T cells, activated B cells, and mature dendritic cells (4, 5). Its homophilic interaction induces NK, CTL, and B cell activation (4-7). In human NK cells, activated CRACC transmits signals following association with the adaptor protein EAT-2 (8).

References
  1. Veillette, A. (2006) Immunol. Rev. 214:22.
  2. Tovar, V. et al. (2002) Immunogenetics 54:394.
  3. Murphy, J.J. et al. (2002) Biochem. J. 361:431.
  4. Bouchon, A. et al. (2001) J. Immunol. 167:5517.
  5. Lee, J.K. et al. (2007) J. Immunol. 179:4672.
  6. Kumaresan, P.R. et al. (2002) Mol. Immunol. 39:1.
  7. Stark, S. and C. Watzl (2006) Int. Immunol. 18:241.
  8. Tassi, H. and M. Colonna (2005) J. Immunol. 175:7996.
Entrez Gene IDs
57823 (Human); 75345 (Mouse)
Alternate Names
19A; CD2 subset 1; CD2-like receptor activating cytotoxic cells; CD319 antigen; CD319; CRACC; CRACCCD2-like receptor-activating cytotoxic cells; CS119A24 protein; Membrane protein FOAP-12; novel LY9 (lymphocyte antigen 9) like protein; Novel Ly9; Protein 19A; SLAM family member 7; SLAMF7

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF and earn rewards!

Have you used Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review